2021 - CCG Updates & Insights
-
Seeing Cancer Through New Lenses: A Broader Spectrum of Cancer Targets
Identifying new targets and therapies for cancers will require thinking beyond the proverbial oncogene. Researchers from NCI’s Cancer Target Discovery and Development (CTD2) Network discuss new ways to model cancer and its potential vulnerabilities.
-
The Serendipitous Off-Target Explorer – Researcher Interview with Jason Sheltzer
Identifying the “targets” for targeted therapy is a major challenge in precision medicine research. Dr. Jason Sheltzer discusses how he inadvertently uncovered mischaracterized cancer targets and what his findings may mean for cancer drug development.
-
Uncovering How HPV Alters the Genome in Ugandan Cervical Cancer Patients
The molecular mechanisms by which HPV infection leads to cancer, especially in low- and middle-income countries experiencing high incidence and mortality rates, have yet to be clearly delineated. A recent genomic, epigenomic, and transcriptomic study of cervical tumors from Ugandan patients looks at specific types of HPV and the genomic alterations they cause.
-
Next-Gen Technologies for Next-Gen Cancer Models, a PANACEA Database for Identifying Drug Off-Targets, and Updates to the CTD^2 and HCMI Programs: February OCG e-Newsletter
A new program developing technologies facilitating next-generation cancer model usage, new features and functions from the Cancer Target Discovery and Development (CTD^2) Program, an off-target discovery DREAM Challenge, and more from the February 2021 edition of the Office of Cancer Genomics (OCG) e-Newsletter.
-
NCI Genomic Data Commons: A Community Resource for Cancer Research
A short time ago the Genomic Data Commons (GDC) was just a dream. CCG Director Lou Staudt describes what the GDC team has built so far: an interactive data system with genomic data processing pipelines for all types of researchers to use.